[Residual risk in cardiovascular prevention].

Despite meaningful progress in the identification of risk factors and the development of highly effective prevention tools, the residual risk of cardiovascular events remains high (about 60-70% in the major outcome trials dealing with statins). Awareness of this problem can properly orient the search for new effective and efficient preventive strategies.